A Clinical Investigation of a Topical Moisturizer on Skin Barrier Function in Adults With Sensitive Skin

Inclusion Criteria: * Adults aged 18 to 55 years, inclusive, of any sex. * Self-declared sensitive skin affecting the body, characterized by unpleasant sensations such as burning, stinging, itching, tingling, tightness, or irritation in response to products or environmental triggers. * Must present a TEWL value ≥15 g/m2/h on a volar forearm at the screening visit (T-7). * Approximately 40-60% of enrolled participants should have Fitzpatrick skin types I-III, and approximately 40-60% should have Fitzpatrick skin types IV-VI. * Must agree to complete a minimum 7-day washout period prior to baseline. * Must agree to avoid body skincare products, moisturizers, hydrating gels, or prohibited topical products on both forearms during washout. * Must agree to use sponsor-provided SPF 30 sunscreen on both forearms beginning at least 7 days before baseline and continuing throughout study participation. * Must be willing and able to comply with all study requirements, including clinic visits, product use, questionnaires, and sample collection procedures. * Must provide written informed consent prior to any study-specific procedure. * Must be willing to apply study products twice daily (morning and evening) for 28 consecutive days and maintain diary compliance. Exclusion Criteria: * Pregnancy, breastfeeding, or planning pregnancy during the study. * Active dermatologic disease on the forearms, visible scars, or tattoos that interfere with measurement. * History of chronic inflammatory or autoimmune conditions (rheumatoid arthritis, lupus, psoriasis, IBD, ankylosing spondylitis, multiple sclerosis). * Active cancer or cancer treatment within the past 5 years, with the exception of localized non-melanoma skin cancer. * Diagnosis of primary or acquired immunodeficiency. * Use of systemic corticosteroids (oral or injected) within 4 weeks pre-enrollment, or anticipated use during the study. * Use of biologics for inflammatory conditions within 12 weeks pre-enrollment (including TNF inhibitors, IL-17 inhibitors, IL-23 inhibitors, IL-4/IL-13 inhibitors, dupilumab, lebrikizumab, tralokinumab, JAK inhibitors, and IL-1 blockers). * Use of systemic immunosuppressants within 8 weeks pre-enrollment (methotrexate, cyclosporine, mycophenolate, azathioprine, systemic tacrolimus). * Use of systemic antibiotics within 4 weeks pre-enrollment, or anticipated use during the study. * Regular use of oral NSAIDs (defined as more than 2 days per week on average) within 2 weeks pre-enrollment or anticipated regular use during the study. Occasional use for acute conditions is permitted with logging. * Daily aspirin use, including low-dose aspirin for cardiovascular prophylaxis. * Use of topical corticosteroids, calcineurin inhibitors, or other prescription anti- inflammatory topicals on the forearms within 4 weeks pre-enrollment. * Use of topical retinoids, alpha hydroxy acids, beta hydroxy acids, or other active exfoliants on the forearms within 4 weeks pre-enrollment. * Active smoking (including vaping and recent cessation within 6 months). * Heavy alcohol use, defined as more than 8 drinks per week. * Surgery under general anaesthesia within the past 4 weeks. * Vaccination within 2 weeks pre-enrollment. * Excessive UV exposure (sunbathing, tanning beds) within 4 weeks pre-enrollment. * Enrolled in another clinical trial within the 4 weeks pre-enrollment or during the study period.